Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBO-PEP: Ervebo + Inmazeb for Post-exposure Prophylaxis of Ebola Virus Disease
NCT06841614Phase 3Not yet recruiting
- Sponsor
- ANRS
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of REGN-EB3 in Ebola virus disease (EVD) (2 arms), sponsored by ANRS. Primary endpoint: Proportion of participants with EBOV PCR-confirmed symptomatic EVD at 21 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
REGN-EB3
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT06841614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841614.